Note: Descriptions are shown in the official language in which they were submitted.
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
METHODS AND COMPOSITIONS FOR DELIVERY OF
IMMUNOTHERAPY AGENTS ACROSS THE BLOOD-
BRAIN BARRIER TO TREAT BRAIN CANCER
CLAIM OF PRIORITY
This application claims the benefit of U.S. Provisional Application Serial No.
62/959,625, filed on January 10, 2020. The entire contents of the foregoing
are
incorporated herein by reference.
TECHNICAL FIELD
Described herein are sequences that enhance permeation of immunotherapy
agents across the blood brain barrier, compositions comprising the sequences,
and
methods of use thereof to treat brain cancer, e.g., glioblastoma (GBM).
BACKGROUND
Glioblastoma multiforme (GBM) is the most common and deadly brain tumor
in adults with a median overall survival of only 15 months'. Approximately
12,000
new GBM cases are diagnosed every year in the United States with an incidence
rate
of 3.2 per 100,000 population2. Despite significant progress made in
understanding
the histology, molecular landscape and tumor microenvironment of GBM3-6, there
have been few therapeutic advances since 2005. One critical obstacle in
turning our
wealth of knowledge on GBM into effective therapy is the inefficient drug
delivery to
the GBM tumor site. Intravenous administration is a convenient and widely
applicable
route of drug administration that, in theory, could achieve good tumor
coverage as
GBM tumor is well vascularized structurally'. However, designing drugs that
cross
the blood-brain barrier (BBB) and/or blood-tumor barrier remains challenging.
SUMMARY
Glioblastoma is an extremely deadly brain cancer that is difficult to treat
using
conventional methods. Systemically administered cancer gene therapy is a new
treatment paradigm for tackling glioblastoma. Described herein are brain-
penetrant
AAV viral vectors engineered to establish an intravascular gene delivery
platform for
glioblastoma gene therapy, e.g., to systemically delivers PD-Li antibodies for
the
treatment of glioblastoma.
1
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
Thus, provided herein are methods for delivering an immunotherapy agent to a
cancer in a subject. The methods include administering to the subject an adeno-
associated virus (AAV) comprising (i) a capsid protein comprising an amino
acid
sequence that comprises at least four contiguous amino acids from the sequence
TVSALFK (SEQ ID NO:8); TVSALK (SEQ ID NO:4); KLASVT (SEQ ID NO:83);
or KFLASVT (SEQ ID NO:84), and (ii) a transgene encoding an immunotherapy
agent, optionally wherein the cancer cell is in the brain of a human subject.
In some embodiments, the amino acid sequence comprises at least five
contiguous amino acids from the sequence TVSALK (SEQ ID NO:4); TVSALFK
(SEQ ID NO:8); KLASVT (SEQ ID NO:83); or KFLASVT (SEQ ID NO:84).
In some embodiments, the amino acid sequence comprises at least six
contiguous amino acids from the sequence TVSALK (SEQ ID NO:4); TVSALFK
(SEQ ID NO:8); KLASVT (SEQ ID NO:83); or KFLASVT (SEQ ID NO:84).
Also provided herein are methods for delivering an immunotherapy agent to a
cancer in a subject. The methods include administering to the subject an adeno-
associated virus (AAV) comprising (i) a capsid protein comprising an amino
acid
sequence that comprises at least four contiguous amino acids from the sequence
V[S/p][A/m/t/]L (SEQ ID NO:79), TV[S/p][A/m/t/]L (SEQ ID NO:80),
TV[S/p][A/m/t/]LK (SEQ ID NO:81), or TV[S/p][A/m/t/]LFK. (SEQ ID NO:82), and
(ii) a transgene encoding an immunotherapy agent, optionally wherein the
cancer cell
is in the brain of a human subject.
In some embodiments, the targeting sequence comprises VPALR (SEQ ID
NO:1); VSALK (SEQ ID NO:2); TVPALR (SEQ ID NO:3); TVSALK (SEQ ID
NO:4); TVPMLK (SEQ ID NO:12); TVPTLK (SEQ ID NO:13); FTVSALK (SEQ ID
NO:5); LTVSALK (SEQ ID NO:6); TVSALFK (SEQ ID NO:8); TVPALFR (SEQ ID
NO:9); TVPMLFK (SEQ ID NO:10) or TVPTLFK (SEQ ID NO:11).
In some embodiments, the transgene encoding an immunotherapy agent
encodes an antibody targeting PD-1 or PD-Li.
In some embodiments, the subject is a mammalian subject.
In some embodiments, the AAV is AAV9.
In some embodiments, the AAV9 comprises AAV9 VP1.
In some embodiments, the targeting sequence is inserted in a position
corresponding to amino acids 588 and 589 of AAV9 VP1 comprising SEQ ID NO:85.
2
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
In some embodiments, the cell is in the brain of the subject, and the AAV is
administered by parenteral delivery; intracerebral; or intrathecal delivery.
In some embodiments, the parenteral delivery is via intravenous,
intraarterial,
subcutaneous, intraperitoneal, or intramuscular delivery.
In some embodiments, the intrathecal delivery is via lumbar injection,
cisternal magna injectio, or intraparenchymal injection.
In some embodiments, the methods further include administering
chemotherapy, radiation, and/or surgical resection to the subject.
In some embodiments, the chemotherapy comprises temozolamide, lomustine,
or a combination thereof.
Unless otherwise defined, all technical and scientific terms used herein have
the same meaning as commonly understood by one of ordinary skill in the art to
which this invention belongs. Methods and materials are described herein for
use in
the present invention; other, suitable methods and materials known in the art
can also
be used. The materials, methods, and examples are illustrative only and not
intended
to be limiting. All publications, patent applications, patents, sequences,
database
entries, and other references mentioned herein are incorporated by reference
in their
entirety. In case of conflict, the present specification, including
definitions, will
control.
Other features and advantages of the invention will be apparent from the
following detailed description and figures, and from the claims.
DESCRIPTION OF DRAWINGS
FIGS. 1A-1C depict an exemplary strategy of engineering AAV9 by inserting
cell-penetrating peptides (CPPs) into its capsid. Fig. lA is a 3D model of an
AAV9
virus. Individual CPP inserted into the capsid between amino acids 588 and 589
(VP1
numbering) will be displayed at the 3-fold axis where receptor binding
presumably
occurs. FIG. 1B illustrates the method of individual AAV production. Three
plasmids
including pRC (engineered or not), pHelper and pAAV are co-transfected into
HEK
293T cells, with AAVs harvested and purified using iodixanol gradient. FIG. 1C
is a
vector diagram of an exemplary vector comprising a sequence encoding an anti-
PDL1
antibody.
FIGS. 2A-2B depict representative images of mouse brain sections (FIG. 2A)
and their quantitative analysis (FIG. 2B) after intravenous administration of
low-dose
3
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
candidate AAVs. Mice with mixed genetic background are used. Candidate AAVs
differs in their inserted CPPs (see Table 3), but all express nuclear red
fluorescent
protein (RFP) as reporter. Candidate AAVs with low production yields are
excluded
for further screening. The dose of AAV is lx1010 vg (viral genome) per animal.
Each
white dot in FIG. 2A represents a RFP-labeled cell. In FIG. 2B, * P< 0.05, vs.
AAV9,
ANOVA.
FIGS. 2C-2D depict representative images of mouse brain sections (FIG. 2C)
and their quantitative analysis (FIG. 2D) after intravenous administration of
AAV.CPP.11 and AAV.CPP.12 in a repeat experiment. AAV.CPP.11 and AAV.CPP.12
contain CPPs BIP1 and BIP2 respectively (see Table 3). The doses of the AAVs
are
increased to lx1011 vg per animal. Candidate AAVs express nuclear red
fluorescent
protein (RFP) as reporter. Each white dot in FIG. 2C represents a RFP-labeled
cell. In
FIG. 2D, * P< 0.05, ** P< 0.01, vs. AAV9, ANOVA.
FIG. 3A depicts the optimization of the BIP targeting sequence in order to
further engineer AAV9 towards better brain transduction. BIP1 (VPALR, SEQ ID
NO:1), which enables AAV9 to transduce brain more efficiently (as in
AAV.CPP.11),
is derived from the protein Ku70 in rats. Human, mouse and rat Ku70 proteins
differ
in their exact amino acid sequences. BIP2 (VSALK, SEQ ID NO:2) as in
AAV.CPP.12
is a "synthetic" peptide related to BIP1. Further engineering focuses on the
VSALK
sequence in the hope of minimizing species specificity of final engineered
AAV. To
generate new targeting sequence, amino acids of interest are added to the
VSALK
sequence, and in other cases positions of individual amino acids are switched.
All new
BIP2-derived sequences are again inserted into the AAV9 capsid to generate new
candidate AAVs for screening. Sequences appearing in order are SEQ ID NOs: 69,
70, 71, 1-6, 72, 7, and 8.
FIGS. 3B-3C depict representative images of mouse brain sections (FIG. 3B)
and their quantitative analysis (FIG. 3C) after intravenous administration of
more
candidate AAVs. All candidate AAVs express nuclear red fluorescent protein
(RFP) as
reporter. The dose of AAV is lx1011 vg per animal. Each white dot in FIG. 3B
represents a RFP-labeled cell. AAV.CPP.16 and AAV.CPP.21 were identified as
top
hits with their robust and widespread brain transduction. In FIG. 3C, * P<
0.05, ** P<
0.01, *** P< 0.001, vs. AAV9, ANOVA.
4
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
FIG. 3D depicts quantitative analysis of transduction efficiency in the liver
after intravenous administration of candidate AAVs. Percentage of transduced
liver
cells is presented. The dose of AAV is lx1011 vg per animal. *** P< 0.001, vs.
AAV9, ANOVA.
FIGS. 4A-4E depict screening of selected candidate AAVs in an in vitro
spheroid model of human blood-brain barrier. FIG. 4A illustrates the spheroid
comprising human microvascular endothelial cells, which forms a barrier at the
surface, and human pericyte and astrocytes inside the spheroid. Candidate AAVs
were
assessed for their ability to penetrate from the surrounding medium into the
inside of
.. the spheroid and to transduce the cells inside. FIG. 4B-4D shows images of
AAV9
(FIG. 4B), AAV.CPP.16 (FIG. 4C) and AAV.CPP.21 (FIG. 4D) treated spheroids.
FIG.
4E shows relative RFP intensity of different AAV treated spheroids. *** P<
0.001, vs.
AAV9, ANOVA.
FIGS. 5A-5B depict representative images of brain sections (FIG. 5A) and
their quantitative analysis (FIG. 5B) after intravenous administration of
AAV9,
AAV.CPP.16 and AAV.CPP.21 in C57BL/6J inbred mice. All candidate AAVs express
nuclear red fluorescent protein (RFP) as reporter. The dose of AAV is lx1012
vg per
animal. Each white dot in FIG. 5A represents a RFP-labeled cell. In FIG. 5B, *
P<
0.05, *** P< 0.001, ANOVA.
FIGS. 6A-6B depict representative images of brain sections (FIG. 6A) and
their quantitative analysis (FIG. 6B) after intravenous administration of
AAV9,
AAV.CPP.16 and AAV.CPP.21 in BALB/cJ inbred mice. All candidate AAVs express
nuclear red fluorescent protein (RFP) as reporter. The dose of AAV is lx1012
vg per
animal. Each white dot in FIG. 6A represents a RFP-labeled cell. In FIG. 6B,
*** P<
0.001, ANOVA.
Figs. 7A-7B depict representative images of brain sections (FIG. 7A) and their
quantitative analysis (FIG. 7B) after intravenous administration of high-dose
AAV.CPP.16 and AAV.CPP.21 in C57BL/6J inbred mice. Both candidate AAVs
express nuclear red fluorescent protein (RFP) as reporter. The dose of AAV is
4 x1012
vg per animal. Each white dot in FIG. 7A represents a RFP-labeled cell. In
FIG. 7B, *
P< 0.05, Student test.
FIG. 8A shows AAV.CPP.16 and AAV.CPP.21 transduce adult neurons (labeled
by a NeuN antibody) across multiple brain regions in mice including the
cortex,
5
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
midbrain and hippocampus. Transduced neurons are co-labeled by NeuN antibody
and RFP. AAVs of 4 x1012 vg were administered intravenously in adult C57BL/6J
mice (6 weeks old).
FIG. 8B depicts that AAV.CPP.16 and AAV.CPP.21 show enhanced ability vs.
AAV9 in targeting the spinal cord and motor neurons in mice. AAVs of 4 x101
vg
were administered intravenously into neonate mice (1 day after birth). Motor
neurons
in the ventral horn of the spinal cord were visualized using CHAT antibody
staining.
Co-localization of RFP and CHAT signals suggests specific transduction of the
motor
neurons.
FIG. 9A depicts that AAV.CPP.16 shows enhanced ability vs. AAV9 in
targeting the heart in adult mice. AAVs of 1 x1011 vg were administered
intravenously
in adult C57BL/6J mice (6 weeks old). Percentage of RFP-labeled cells relative
to all
DAPI-stained cells is presented. * P< 0.05, Student test.
FIG. 9B depicts that AAV.CPP.16 shows enhanced ability vs. AAV9 in
targeting the skeletal muscle in adult mice. AAVs of lx 1011 vg were
administered
intravenously in adult C57BL/6J mice (6 weeks old). Percentage of RFP-labeled
cells
relative to all DAPI-stained cells is presented. * P< 0.05, Student test.
FIG. 9C depicts that AAV.CPP.16 shows enhanced ability vs. AAV9 in
targeting the dorsal root ganglion (DRG) in adult mice. AAVs of lx1011 vg were
administered intravenously in adult C57BL/6J mice (6 weeks old). Percentage of
RFP-labeled cells relative to all DAPI-stained cells is presented. * P< 0.05,
Student
test.
FIG. 10A depicts that AAV.CPP.16 and AAV.CPP.21 show enhanced ability vs.
AAV9 to transduce brain cells in primary visual cortex after intravenous
administration in non-human primates. 2 x 1013 vg/kg AAVs-CAG-AADC (as
reporter gene) were injected intravenously into 3 months old cynomolgus
monkeys
with low pre-existing neutralizing antibody. AAV-transduced cells (shown in
black)
were visualized using antibody staining against AADC. Squared areas in the
left
panels are enlarged as in the right panels. AAV.CPP.16 transduced
significantly more
cells vs. AAV9. AAV.CPP.21 also transduced more cell vs. AAV9 although its
effect
was less evident in comparison with AAV.CPP.16.
FIG. 10B depicts that AAV.CPP.16 and AAV.CPP.21 show enhanced ability vs.
AAV9 to transduce brain cells in parietal cortex after intravenous
administration in
6
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
non-human primates. 2 x 1013 vg/kg AAVs-CAG-AADC (as reporter gene) were
injected intravenously into 3 months old cynomolgus monkeys with low pre-
existing
neutralizing antibody. AAV-transduced cells (shown in black) were visualized
using
antibody staining against AADC. Squared areas in the left panels are enlarged
as in
the right panels. AAV.CPP.16 transduced significantly more cells vs. AAV9.
AAV.CPP.21 also transduced more cell vs. AAV9 although its effect was less
evident
in comparison with AAV.CPP.16.
FIG. 10C depicts that AAV.CPP.16 and AAV.CPP.21 show enhanced ability vs.
AAV9 to transduce brain cells in thalamus after intravenous administration in
non-
human primates. 2 x 1013 vg/kg AAVs-CAG-AADC (as reporter gene) were injected
intravenously into 3 months old cynomolgus monkeys with low pre-existing
neutralizing antibody. AAV-transduced cells (shown in black) were visualized
using
antibody staining against AADC. Squared areas in the left panels are enlarged
as in
the right panels. AAV.CPP.16 transduced significantly more cells vs. AAV9.
AAV.CPP.21 also transduced more cell vs. AAV9 although its effect was less
evident
in comparison with AAV.CPP.16.
FIG. 10D depicts that AAV.CPP.16 and AAV.CPP.21 show enhanced ability vs.
AAV9 to transduce brain cells in cerebellum after intravenous administration
in non-
human primates. 2 x 1013 vg/kg AAVs-CAG-AADC (as reporter gene) were injected
intravenously into 3 months old cynomolgus monkeys with low pre-existing
neutralizing antibody. AAV-transduced cells (shown in black) were visualized
using
antibody staining against AADC. Squared areas in the left panels are enlarged
as in
the right panels. Both AAV.CPP.16 and AAV.CPP.21 transduced significantly more
cells vs. AAV9.
FIGS. 11A-11B depict that AAV.CPP.16 and AAV.CPP.21 do not bind to
LY6A. LY6A serves as a receptor for AAV.PHP.B and its variants including
AAV.PHP.eB (as in U59102949, U520170166926) and mediates AAV.PHP.eB's
robust effect in crossing the BBB in certain mouse strains (Hordeaux et al.
Mol Ther
2019 27(5):912-921; Huang et al. 2019, dx.doi.org/10.1101/538421). Over-
expressing
mouse LY6A in cultured 293 cells significantly increases binding of AAV.PHP.eB
to
the cell surface (FIG. 11A). On the contrary, over-expressing LY6A does not
increase
viral binding for AAV9, AAV.CPP.16 or AAV.CPP.21 (FIG. 11B). This suggests
AAV.CPP.16 or AAV.CPP.21 does not share LY6A with AAV.PHP.eB as a receptor.
7
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
FIGS. 12A-12C depict that AAV.CPP.21 can be used to systemically deliver a
therapeutic gene into brain tumor in a mouse mode of glioblastoma (GBM). As in
FIG. 11A, intravenously administered AAV.CPP.21-H2BmCherry was shown to target
tumor mass, especially the tumor expanding frontier (FIG. 12A). In FIG. 11B
(images) and FIG. 11C (quantitative analysis), using AAV.CPP.21 to
systemically
deliver the "suicide gene" HSV.TK1 results in shrinkage of brain tumor mass,
when
combined with the pro-drug ganciclovir. HSV.TK1 turns the otherwise "dormant"
ganciclovir into a tumor-killing drug. * P< 0.05, Student test.
FIG. 13 depicts that when injected locally into adult mouse brain, AAV.CPP.21
resulted in more widespread and robust transduction of brain tissue in
comparison
with AAV9. Intracerebral injection of AAVs (1x1011 vg) was performed in adult
mice
(>6 weeks old) and brain tissues were harvested and examined 3 weeks after AAV
injection. ** P< 0.01, Student test.
FIG. 14 is a set of images comparing delivery efficiency to the GBM tumor
microenvironment in a mouse model using AAV9 (top) and AAV.CPP16 (bottom). As
can be seen in the insets (right), AAV.CPP16 provided greater delivery
efficacy.
FIGS. 15A-C show that AAV.CPP.16-antiPD-L1 mediated immunotherapy
prolonged survival in a murine GBM model. FIG. 15A, schematic of experimental
protocol. FIG. 15B, survival in animals treated as indicated. FIG. 15C, long
term
survival in animals treated with AAV.CPP16-anti-PDL1. LTS: long-term survival.
FIGS. 16A-C show that GBM tumors were eradicated in all of the long-term
surviving mice. FIG. 16A, H&E staining of brain sections both posterior and
anterior
to the tumor injection site. No residual GBM in any section. FIG. 16B,
Bioluminescent imaging 7 days after tumor implant suggesting success of
initial
tumor implantation. FIG. 16C, GBM tumor implantation site with scar-like
tissues.
FIGS. 17A-17B show expression of HA-tagged antiPD-L1 antibody in GBM
tumor as measured by Western blotting. AAVs of 1e12 vg or PBS were injected
intravenously 5 days after tumor implantation in mice. Tumor tissues were
harvested
14 days after IV injection. The intensities of HA tag staining (FIG. 17A) were
quantified as measurement of antiPD-L1 antibody expression (FIG. 17B).
DETAILED DESCRIPTION
Difficulties associated with delivery across the BBB have hindered
development of therapeutic agents to treat brain disorders including cancer.
Adeno-
8
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
associated virus (AAV) has emerged as an important research and clinical tool
for
delivering therapeutic genes to the brain, spinal cord and the eye; see, e.g.,
US9102949; US 9585971; and US20170166926. Gene therapy mediated by AAVs has
made significant progress with the recent approvals of Luxturna and Zolgensma.
The
approval of Zolgensma for intravascular treatment of spinal muscular atrophy
patients
under two years of age is particular encouraging, as it demonstrates the
feasibility of
using BBB-crossing AAV vectors for systemic gene therapy of the central
nervous
system (CNS). Despite of its success in young patients, AAV9, which is the AAV
serotype used in Zolgensma, suffers from low efficiency of BBB crossing,
particularly
in adults, which limits its application for other CNS diseases". Described
herein are
next-generation, brain-penetrant AAV vectors (namely, AAV.CPP16) that achieves
at
least 5-10 fold enhancement over current industrial standard (i.e. AAV9) in
both
rodents and non-human primates, that can be used for a new BBB-crossing AAV
platform for GBM cancer gene therapy.
Through rational design and targeted screening on the basis of known cell-
penetrating peptides (CPPs) (see, e.g., Gomez et al., Bax-inhi biting peptides
derived
from Ku70 and cell-penetrating pentapeptides. Biochem. Soc. Trans. 2007;35(Pt
4):797-801), targeting sequences have been discovered that, when engineered
into the
capsid of an AAV, improved the efficiency of gene delivery to the brain by up
to three
orders of magnitude. These methods were used to engineer AAV vectors that
dramatically reduce tumor size in an animal model of glioblastoma.
In addition, the brain is "immune privileged", which renders immunotherapy
of GBM challenging. "Priming" the immune response is desirable to turn the
immunologically "cold" GBM tumor into an immunogenic, "hot" one. The present
methods make use of the vectors described herein to deliver immunotherapeutics
that
may achieve just that, e.g., anti-PD-Li antibodies. Without wishing to be
bound by
theory, it is believed that the AAV vector itself "primes" the immune system
by
increasing tumor infiltration of cytotoxic T cells while the antiPD-L1
antibody
expressed at the tumor site, and in the CNS at large, activates the otherwise
"exhausted" T cells.
Targeting Sequences
The present methods identified a number of potential targeting peptides that
enhance permeation through the BBB, e.g., when inserted into the capsid of an
AAV,
9
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
e.g., AAV1, AAV2, AAV8, or AAV9, or when conjugated to a biological agent,
e.g.,
an antibody or other large biomolecule, either chemically or via expression as
a fusion
protein.
In some embodiments, the targeting peptides comprise sequences of at least 5
amino acids. In some embodiments, the amino acid sequence comprises at least
4,
e.g., 5, contiguous amino acids of the sequences VPALR (SEQ ID NO:1) and
VSALK (SEQ ID NO:2).
In some embodiments, the targeting peptides comprise a sequence of Xi X2 X3
X4 X5, wherein:
(i) Xi, X2, X3, X4 are any four non-identical amino acids of V, A, L, I, G,
P, S, T,
or M; and
(ii) X5 is K, R, H, D, or E (SEQ ID NO:73).
In some embodiments, the targeting peptides comprise sequences of at least 6
amino acids. In some embodiments, the amino acid sequence comprises at least
4,
e.g., 5 or 6 contiguous amino acids of the sequences TVPALR (SEQ ID NO:3),
TVSALK (SEQ ID NO:4), TVPMLK (SEQ ID NO:12) and TVPTLK (SEQ ID
NO:13).
In some embodiments, the targeting peptides comprise a sequence of Xi X2 X3
X4 X5 X6, wherein:
(i) Xi is T;
(ii) X2, X3, X4, X5 are any four non-identical amino acids of V, A, L, I,
G, P, S, T,
or M; and
(iii) X6 is K, R, H, D, or E (SEQ ID NO:74).
In some embodiments, the targeting peptides comprise a sequence of Xi X2 X3
X4 X5 X6, wherein:
(i) Xi, X2, X3, X4 are any four non-identical amino acids from V, A, L, I,
G, P, S,
T, or M;
(ii) X5 is K, R, H, D, or E; and
(iii) X6 is E or D (SEQ ID NO:75).
In some embodiments, the targeting peptides comprise sequences of at least 7
amino acids. In some embodiments, the amino acid sequence comprises at least
4,
e.g., 5, 6, or 7 contiguous amino acids of the sequences FTVSALK (SEQ ID
NO:5),
LTVSALK (SEQ ID NO:6), TVSALFK (SEQ ID NO:8), TVPALFR (SEQ ID NO:9),
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
TVPMLFK (SEQ ID NO:10) and TVPTLFK (SEQ ID NO:11). In some other
embodiments, the targeting peptides comprise a sequence of Xi X2 X3 X4 X5 X6
X7,
wherein:
(i) Xi is F, L, W, or Y;
(i1) X2 is T;
(iii) X3, X4, Xs, X6 are any four non-identical amino acids of V, A, L, I,
G, P, S, T,
or M; and
(iv) X7 is K, R, H, D, or E (SEQ ID NO:76).
In some embodiments, the targeting peptides comprise a sequence of Xi X2 X3
X4 X5 X6 X7, wherein:
(i) Xi is T;
(ii) X2, X3, X4, Xs are any four non-identical amino acids of V, A, L, I,
G, P, S, T,
or M;
(iii) X6 is K, R, H, D, or E; and
(11/) X7 is E or D (SEQ ID NO:77).
In some embodiments, the targeting peptides comprise a sequence of Xi X2 X3
X4 X5 X6 X7, wherein:
(i) Xi, X2, X3, X4 are any four non-identical amino acids of V, A, L,
I, G, P, S, T,
or M;
(i1) X5 is K, R, H, D, or E;
(iii) X6 is E or D; and
(iv) X7 is A or I (SEQ ID NO:78).
In some embodiments, the targeting peptides comprise a sequence of
V[S/p][A/m/t/]L (SEQ ID NO:79), wherein the upper case letters are preferred
at that
position. In some embodiments, the targeting peptides comprise a sequence of
TV[S/p][A/m/t/]L (SEQ ID NO:80). In some embodiments, the targeting peptides
comprise a sequence of TV[S/p][A/m/t/]LK (SEQ ID NO:81). In some embodiments,
the targeting peptides comprise a sequence of TV[S/p][A/m/t/]LFK. (SEQ ID
NO:82).
In some embodiments, the targeting peptide does not consist of VPALR (SEQ
ID NO:1) or VSALK (SEQ ID NO:2).
Specific exemplary amino acid sequences that include the above mentioned 5,
6, or 7-amino acid sequences are listed in Table 1.
11
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
TABLE 1 - Targeting Sequences
SEQ ID NO: Targeting Peptide Sequence
1. VPALR
2. VSALK
3. TVPALR
4. TVSALK
5. FTVSALK
6. LTVSALK
7. TFVSALK
8. TVSALFK
9. TVPALFR
10. TVPMLFK
11. TVPTLFK
12. TVPMLK
13. TVPTLK
14. VPMLK
15. VP TLK
16. VPMLKE
17. VP TLKD
18. VPALRD
19. VSALKE
20. VSALKD
21. TAVSLK
22. TALVSK
23. TVL S AK
24. TLVSAK
25. TMVPLK
26. TMLVPK
27. TVLPMK
28. TLVPMK
29. TTVPLK
30. TTLVPK
31. TVLPTK
32. TLVPTK
33. TAVPLR
34. TALVPR
35. TVLPAR
36. TLVPAR
37. TAVSLKE
38. TALVSKE
39. TVL S AKE
40. TLVSAKE
41. TMVPLKE
42. TMLVPKE
43. TVLPMKE
44. TLVPMKE
45. TTVPLKD
46. TTLVPKD
12
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
SEQ ID NO: Targeting Peptide Sequence
47. TVLPTKD
48. TLVPTKD
49. TAVPLRD
50. TALVPRD
51. TVLPARD
52. TLVPARD
53. TAVSLFK
54. TALVSFK
55. TVLSAFK
56. TLVSAFK
57. TMVPLFK
58. TMLVPFK
59. TVLP1VIFK
60. TLVP1VIFK
61. TTVPLFK
62. TTLVPFK
63. TVLPTFK
64. TLVPTFK
65. TAVPLFR
66. TALVPFR
67. TVLPAFR
68. TLVPAFR
Targeting peptides including reversed sequences can also be used, e.g.,
KLASVT (SEQ ID NO:83) and KFLASVT (SEQ ID NO:84).
Targeting peptides disclosed herein can be modified according to the methods
known in the art for producing peptidomimetics. See, e.g., Qvit et al., Drug
Discov
Today. 2017 Feb; 22(2): 454-462; Farhadi and Hashemian, Drug Des Devel Ther.
2018; 12: 1239-1254; Avan et al., Chem. Soc. Rev., 2014,43, 3575-3594; Pathak,
et
al., Indo American Journal of Pharmaceutical Research, 2015. 8; Kazmierski,
W.M.,
ed., Peptidomimetics Protocols, Human Press (Totowa NJ 1998); Goodman et al.,
eds., Houben-Weyl Methods of Organic Chemistry: Synthesis of Peptides and
Peptidomimetics, Thiele Verlag (New York 2003); and Mayo et al., J. Biol.
Chem.,
278:45746 (2003). In some cases, these modified peptidomimetic versions of the
peptides and fragments disclosed herein exhibit enhanced stability in vivo,
relative to
the non-peptidomimetic peptides.
Methods for creating a peptidomimetic include substituting one or more, e.g.,
all, of the amino acids in a peptide sequence with D-amino acid enantiomers.
Such
sequences are referred to herein as "retro" sequences. In another method, the
N-
terminal to C-terminal order of the amino acid residues is reversed, such that
the order
13
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
of amino acid residues from the N-terminus to the C-terminus of the original
peptide
becomes the order of amino acid residues from the C-terminus to the N-terminus
in
the modified peptidomimetic. Such sequences can be referred to as "inverso"
sequences.
Peptidomimetics can be both the retro and inverso versions, i.e., the "retro-
inverso" version of a peptide disclosed herein. The new peptidomimetics can be
composed of D-amino acids arranged so that the order of amino acid residues
from
the N-terminus to the C-terminus in the peptidomimetic corresponds to the
order of
amino acid residues from the C-terminus to the N-terminus in the original
peptide.
Other methods for making a peptidomimetic include replacing one or more
amino acid residues in a peptide with a chemically distinct but recognized
functional
analog of the amino acid, i.e., an artificial amino acid analog. Artificial
amino acid
analogs include I3-amino acids, I3-substituted I3-amino acids ("I33-amino
acids"),
phosphorous analogs of amino acids, such as V-amino phosphonic acids and V-
amino
phosphinic acids, and amino acids having non-peptide linkages. Artificial
amino
acids can be used to create peptidomimetics, such as peptoid oligomers (e.g.,
peptoid
amide or ester analogues), I3-peptides, cyclic peptides, oligourea or
oligocarbamate
peptides; or heterocyclic ring molecules. Exemplary retro-inverso targeting
peptidomimetics include KLASVT and KFLASVT, wherein the sequences include all
D-amino acids. These sequences can be modified, e.g., by biotinylation of the
amino
terminus and amidation of the carboxy terminus.
AAVs
Viral vectors for use in the present methods and compositions include
recombinant retroviruses, adenovirus, adeno-associated virus, alphavirus, and
lentivirus, comprising the targeting peptides described herein and optionally
a
transgene for expression in a target tissue.
A preferred viral vector system useful for delivery of nucleic acids in the
present methods is the adeno-associated virus (AAV). AAV is a tiny non-
enveloped
virus having a 25 nm capsid. No disease is known or has been shown to be
associated
with the wild type virus. AAV has a single-stranded DNA (ssDNA) genome. AAV
has been shown to exhibit long-term episomal transgene expression, and AAV has
demonstrated excellent transgene expression in the brain, particularly in
neurons.
Vectors containing as little as 300 base pairs of AAV can be packaged and can
14
CA 03167290 2022-07-08
WO 2021/142300 PCT/US2021/012746
integrate. Space for exogenous DNA is limited to about 4.7 kb. An AAV vector
such
as that described in Tratschin et al., Mol. Cell. Biol. 5:3251-3260 (1985) can
be used
to introduce DNA into cells. A variety of nucleic acids have been introduced
into
different cell types using AAV vectors (see for example Hermonat et al., Proc.
Natl.
Acad. Sci. USA 81:6466-6470 (1984); Tratschin et al., Mol. Cell. Biol. 4:2072-
2081
(1985); Wondisford et al., Mol. Endocrinol. 2:32-39 (1988); Tratschin et al.,
J. Virol.
51:611-619 (1984); and Flotte et al., J. Biol. Chem. 268:3781-3790 (1993).
There are
numerous alternative AAV variants (over 100 have been cloned), and AAV
variants
have been identified based on desirable characteristics. In some embodiments,
the
AAV is AAV1, AAV2, AAV4, AAV5, AAV6, AV6.2, AAV7, AAV8, AAV9, rh.10,
rh.39, rh.43 or CSp3; for CNS use, in some embodiments the AAV is AAV1, AAV2,
AAV4, AAV5, AAV6, AAV8, or AAV9. As one example, AAV9 has been shown
to somewhat efficiently cross the blood-brain barrier. Using the present
methods, the
AAV capsid can be genetically engineered to increase permeation across the
BBB, or
into a specific tissue, by insertion of a targeting sequence as described
herein into the
capsid protein, e.g., into the AAV9 capsid protein VP1 between amino acids 588
and
589.
An exemplary wild type AAV9 capsid protein VP1 (Q6JC40-1) sequence is as
follows:
10 20 30 40 50
MAADGYLPDW LEDNLSEGIR EWWALKPGAP QPKANQQHQD NARGLVLPGY
60 70 80 90 100
KYLGPGNGLD KGEPVNAADA AALEHDKAYD QQLKAGDNPY LKYNHADAEF
110 120 130 140 150
25 QERLKEDTSF GGNLGRAVFQ AKKRLLEPLG LVEEAAKTAP
GKKRPVEQSP
160 170 180 190 200
QEPDSSAGIG KSGAQPAKKR LNFGQTGDTE SVPDPQPIGE PPAAPSGVGS
210 220 230 240 250
LTMASGGGAP VADNNEGADG VGSSSGNWHC DSQWLGDRVI TTSTRTWALP
260 270 280 290 300
TYNNHLYKQI SNSTSGGSSN DNAYFGYSTP WGYFDFNRFH CHFSPRDWQR
310 320 330 340 350
LINNNWGFRP KRLNFKLFNI QVKEVTDNNG VKTIANNLTS TVQVFTDSDY
360 370 380 390 400
35 QLPYVLGSAH EGCLPPFPAD VFMIPQYGYL TLNDGSQAVG
RSSFYCLEYF
410 420 430 440 450
PSQMLRTGNN FQFSYEFENV PFHSSYAHSQ SLDRLMNPLI DQYLYYLSKT
460 470 480 490 500
INGSGQNQQT LKFSVAGPSN MAVQGRNYIP GPSYRQQRVS TTVTQNNNSE
510 520 530 540 550
FAWPGASSWA LNGRNSLMNP GPAMASHKEG EDRFFPLSGS LIFGKQGTGR
CA 03167290 2022-07-08
WO 2021/142300 PCT/US2021/012746
560 570 580 590 600
DNVDADKVMI TNEEEIKTTN PVATESYGQV ATNHQSAQAQ AQTGWVQNQG
610 620 630 640 650
ILPGMVWQDR DVYLQGPIWA KIPHTDGNFH PSPLMGGFGM KHPPPQILIK
660 670 680 690 700
NTPVPADPPT AFNKDKLNSF ITQYSTGQVS VEIEWELQKE NSKRWNPEIQ
710 720 730
YTSNYYKSNN VEFAVNTEGV YSEPRPIGTR YLTRNL (SEQ ID
NO: 85)
Thus provided herein are AAV that include one or more of the targeting
peptide sequences described herein, e.g., an AAV comprising a capsid protein
comprising a targeting sequence described herein, e.g., a capsid protein
comprising
SEQ ID NO:1 wherein a targeting peptide sequence has been inserted into the
sequence, e.g., between amino acids 588 and 589.
Immunotherapeutic transgenes
In some embodiments, the AAV also includes a transgene sequence (i.e., a
heterologous sequence) encoding an immunotherapeutic agent, e.g., as described
herein or as known in the art. The transgene is preferably linked to sequences
that
promote/drive expression of the transgene in the target tissue.
Exemplary transgenes for use as immunotherapeutics include those encoding
an immune checkpoint inhibitory antibody or antigen-binding fragment thereof,
e.g.,
single-chain variable fragment (scFv) antibodies that act as checkpoint
inhibitors.
Examples of immunotherapies include, but are not limited to, adoptive T cell
therapies or cancer vaccine preparations designed to induce T lymphocytes to
recognize cancer cells, as well as checkpoint inhibitors such as anti-CD137
antibodies
(e.g., BMS-663513), anti-PD1 antibodies (e.g., Nivolumab, pembrolizumab/MK-
3475, Pidilizumab (CT-011)), anti-PDL1 antibodies (e.g., BMS-936559,
MPDL3280A), or anti-CTLA-4 antibodies (e.g., ipilumimab; see, e.g., Kruger et
al.
(2007) Histol Histopathol. 22(6): 687-96; Eggermont et at. (2010) Semin Oncol.
37(5): 455-9; Klinke (2010) Mol. Cancer. 9:242; Alexandrescu et al. (2010)1
Immunother. 33(6): 570-90; Moschella et at. (2010) Ann N Y Acad Sci. 1194: 169-
78;
Ganesan and Bakhshi (2010) Natl. Med. I India 23(1): 21-7; and Golovina and
Vonderheide (2010) Cancer 1 16(4): 342-7.
Exemplary anti-PD-1 antibodies that can be used in the methods described
herein include those that bind to human PD-1; an exemplary PD-1 protein
sequence is
16
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
provided at NCBI Accession No. NP 005009.2. Exemplary antibodies are described
in U.S. Patent Nos. 8,008,449; 9,073,994; and U.S. Publication No.
2011/0271358,
including, e.g., PF-06801591, AMP-224, BGB-A317, BI 754091, JS001, 1VIEDI0680,
PDR001, REGN2810, SHR-1210, TSR-042, pembrolizumab, nivolumab, avelumab,
Cemiplimab, Spartalizumab, Camrelizumab, Sintilimab, pidilizumab,
Tislelizumab,
Toripalimab, AMP-224, AMP-514, and atezolizumab.
Exemplary anti-CD40 antibodies that can be used in the methods described
herein include those that bind to human CD40; exemplary CD40 protein precursor
sequences are provided at NCBI Accession No. NP 001241.1, NP 690593.1,
NP 001309351.1, NP 001309350.1 and NP 001289682.1. Exemplary antibodies
include those described in International Publication Nos. WO 2002/088186;
WO 2007/124299; WO 2011/123489; WO 2012/149356; WO 2012/111762;
WO 2014/070934; U.S. Publication Nos. 2013/0011405; 2007/0148163;
2004/0120948; 2003/0165499; and U.S. Patent No. 8,591,900; including, e.g.,
dacetuzumab, lucatumumab, bleselumab, teneliximab, ADC-1013, CP-870,893, Chi
Lob 7/4, HCD122, SGN-4, SEA-CD40, BMS-986004, and APX005M. In some
embodiments, the anti-CD40 antibody is a CD40 agonist, and not a CD40
antagonist.
Exemplary anti-PD-Li antibodies that can be used in the methods described
herein include those that bind to human PD-Li; exemplary PD-Ll protein
sequences
are provided at NCBI Accession No. NP 001254635.1, NP 001300958.1, and
NP 054862.1. Exemplary antibodies are described in U.S. Publication No.
2017/0058033; International Publication Nos. WO 2017/118321A1;
WO 2016/061142A1; WO 2016/007235A1; WO 2014/195852A1; and
WO 2013/079174A1, including, e.g., BMS-936559 (MDX-1105), FAZ053, KN035,
Atezolizumab (Tecentriq, MPDL3280A), Avelumab (Bavencio), Durvalumab
(Imfinzi, MEDI-4736), Envafolimab (KN035), CK-301, CS-1001, SHR-1316 (HTI-
1088), CBT-502 (TQB-2450), BGB-A333, and BMS-986189. Non antibody peptide
inhibitors can also be used, e.g., AUNP12, CA-170. See also Akinleye & Rasool,
Journal of Hematology & Oncology 12:92 (2019) doi:10.1186/s13045-019-0779-5.
In some embodiments, the immunotherapeutic is or comprises an antigen
binding portion of anti-PD-Li antibody, e.g., single-chain variable fragment
(scFv)
antibodies against human PD-Li protein (PD-Ll.Hu); an exemplary sequence
encoding an anti-PDL1 antibody scFv is shown in SEQ ID NO:105, or a portion
17
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
thereof, e.g., lacking one, two or more of the signal peptide, HA-tag, and Myc-
tag,
e.g., comprising amino acids (aa) 31-513 of SEQ ID NO:105:
Exemplary anti-PDL1 scFv sequence (Signal peptide (aa 1-21); HA-tag, aa
21-30; Myc-tag, aa 514-523)
METDTLLLWVLLLWVPGSTGDYPYD VPDYA GAQPADDIQMTQ SP SSL SASV
GDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRF SGSGSG
TDFTLTIS SLQPEDFATYYCQQYLYHPATFGQGTKVEIKRGGGGSGGGGSGG
GGSEVQLVESGGGLVQPGGSLRL S C AA S GF TF SD SWIHWVRQAP GKGLEWV
AWISPYGGSTYYAD SVK GRF TI S AD T SKNTAYLQMNSLRAEDTAVYYCARR
HWPGGFDYWGQGTLVTVSAVDEAKSCDKTHTCPPCPAPELLGGPSVFLFPPK
PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN
STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
TLPP SRDELTKNQV SLT CLVKGF YP SDIAVEWESNGQPENNYKT TPPVLD SD G
SFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSL SPGKVDEQKL
ASEEDLN (SEQ ID NO:105).
The following is an exemplary antiPD-L1 nucleic acid sequence (Signal
peptide (nt 1-63); HA-tag, lit 64-90; Mys7t.ag, nt 1540-1569)
ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTTCC
AGGTTCCACTGGTGAC TA TCCA TATGATGTTCCAGA TTA TGCTGGGGCCCAG
CCGGCCGACGACATCCAAATGACCCAGAGTCCATCTAGTCTGTCTGCTTC
GGTAGGTGATAGGGTCACTATTACTTGCAGGGCCTCCCAGGACGTGTCAA
CTGCAGTGGCTTGGTACCAACAGAAGCCCGGGAAAGCTCCCAAACTGCTG
ATCTACTCCGCCAGCTTTCTGTATTCCGGAGTTCCGTCTAGATTTTCCGGA
TCAGGAAGCGGCACGGATTTCACACTCACAATAAGCAGCCTACAACCAGA
GGACTTCGCAACCTACTATTGTCAACAGTACCTGTACCATCCAGCCACCTT
TGGGCAGGGCACCAAGGTGGAAATCAAGCGCGGTGGTGGTGGATCAGGT
GGAGGCGGAAGTGGAGGTGGCGGATCCGAAGTTCAGCTTGTCGAGTCCG
GTGGCGGCCTGGTTCAGCCTGGTGGGTCTTTGCGTCTGTCATGCGCCGCCT
CTGGTTTCACCTTTTCAGACTCTTGGATCCACTGGGTGAGACAGGCCCCAG
GAAAGGGTCTTGAGTGGGTTGCATGGATTAGCCCCTACGGCGGCAGTACA
TATTACGCGGATAGCGTGAAAGGGAGGTTTACCATCAGCGCAGACACGTC
GAAGAACACCGCATACCTCCAGATGAATTCCCTCCGAGCCGAAGATACCG
CCGTGTACTATTGTGCTCGCCGGCATTGGCCTGGCGGCTTCGATTATTGGG
18
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
GACAGGGAACTCTAGTAACAGTGTCGGCTGTCGACGAGGCCAAATCTTGT
GACAAAACTCACACATGCCCACCGTGCCCAGCACCCGAACTCCTGGGGGG
ACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTC
CCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACC
CTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCC
AAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCA
GCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAG
TGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTC
CAAAGCCAAGGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCAT
CCCGGGAT GAGC TGACCAAGAAC CAGGT CAGCCTGACCTGCCTGGTC AAA
GGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCC
GGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCT
TCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGG
AACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACG
CAGAAGAGCCTCTCCCTGTCTCCGGGTAAAGTCGACGAACAAAAACTCA
TE.TCAGAAGAAGATCTGAATTGA (SEQ ID NO:106).
Other antibodies, as well as methods for generating a nucleic acid encoding
such antibodies are known in the art; see, e.g., Li et al., Int J Mol Sci.
2016 Jul; 17(7):
1151; Engeland et al., Mol Ther. 2014 Nov; 22(11): 1949-1959 and the
references
above.
The virus can also include one or more sequences that promote expression of a
transgene, e.g., one or more promoter sequences; enhancer sequences, e.g., 5'
untranslated region (UTR) or a 3' UTR; a polyadenylation site; and/or
insulator
sequences. In some embodiments, the promoter is a brain tissue specific
promoter,
e.g.,a neuron-specific or glia-specific promoter. In certain embodiments, the
promoter
is a promoter of a gene selected to from: neuronal nuclei (NeuN), glial
fibrillary
acidic protein (GFAP), MeCP2, adenomatous polyposis coli (APC), ionized
calcium-
binding adapter molecule 1 (Iba-1), synapsin I (SYN), calcium/calmodulin-
dependent
protein kinase II, tubulin alpha I, neuron-specific enolase and platelet-
derived growth
factor beta chain. In some embodiments, the promoter is a pan-cell type
promoter,
e.g., cytomegalovirus (CMV), beta glucuronidase, (GUSB), ubiquitin C (UBC), or
rous sarcoma virus (RSV) promoter. The woodchuck hepatitis virus
posttranscriptional response element (WPRE) can also be used. In some
19
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
embodiments, a human signal or leader sequence, e.g., an IgK leader sequence
is
used. In some embodiments, a human signal sequence is used instead, as shown
in
the following table (Table adapted from
novoprolabs.com/support/articles/commonly-
used-leader-peptide-sequences-for-efficient-secretion-of-a-recombinant-protein-
expressed-in-mammalian-cells-201804211337.html):
Human SEQ ID
Sequence
Signal sequence NO:
Oncostatin M MGVLLTQRTLLSLVLALLFPSMASM 107
IgG2 H MGWSCIILFLVATATGVHS 108
Secrecon MWWRLWWLLLLLLLLWPMVWA 109*
IgK VIII MDMRVPAQLLGLLLLWLRGARC 110
CD33 MPLLLLLPLLWAGALA 111
tPA MDAMKRGLCCVLLLCGAVFVSPS 112
Human 113
MAFLWLLSCWALLGTTFG
Chymotrypsinogen
Human 114
MNLLLILTFVAAAVA
trypsinogen-2
Human IL-2 MYRMQLLSCIALSLALVTNS 115
Albumin (HSA) MKWVTFISLLFSSAYS 116
Human insulin MALWMRLLPLLALLALWGPDPAAA 117
*, Barash et al., Biochem Biophys Res Commun. 2002 Jun 21;294(4):835-42.
In some embodiments, a secretory sequence that promotes secretion of the
antibody is
used, e.g., as described in von Heijne, J Mol Biol. 1985 Jul 5;184(1):99-105;
Kober et
al., Biotechnol. Bioeng. 2013; 110: 1164-1173; Tsuchiya et al., Nucleic Acids
Research Supplenzent No. 3 261-262 (2003).
In some embodiments, the AAV also has one or more additional mutations
that increase delivery to the target tissue, e.g., the CNS, or that reduce off-
tissue
targeting, e.g., mutations that decrease liver delivery when CNS, heart, or
muscle
delivery is intended (e.g., as described in Pulicherla et al. (2011) Mol Ther
19:1070-
1078); or the addition of other targeting peptides, e.g., as described in Chen
et al.
(2008) Nat Med 15:1215-1218 or Xu et al., (2005) Virology 341:203-214 or
US9102949; US 9585971; and US20170166926. See also Gray and Samulski (2011)
"Vector design and considerations for CNS applications," in Gene Vector Design
and
Application to Treat Nervous System Disorders ed. Glorioso J., editor.
(Washington,
DC: Society for Neuroscience;) 1-9, available at
sfn.org/¨/media/SfN/Documents/Short%20Courses/2011%20Short%20Course%20I/2
011 SC1 Gray.ashx.
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
Methods of Use
The methods and compositions described herein can be used to deliver an
immunotherapeutic composition to a tissue, e.g., to the central nervous system
(brain),
heart, muscle, or dorsal root ganglion or spinal cord (peripheral nervous
system). In
some embodiments, the methods include delivery to specific brain regions,
e.g.,
cortex, cerebellum, hippocampus, substantia nigra, or amygdala. In some
embodiments, the methods include delivery to neurons, astrocytes, and/or glial
cells.
In some embodiments, the methods and compositions, e.g., AAVs, are used to
deliver a nucleic acid sequence encoding an immunotherapeutic to a subject who
has
brain cancer. Brain cancers include gliomas (e.g., glioblastoma multiforme
(GBM)),
metastases (e.g., from lung, breast, melanoma, or colon cancer), meningiomas,
pituitary adenomas, and acoustic neuromas. Thus the methods can include
systemically, e.g., intravenously, administering an AAV (e.g., AAV9)
comprising a
targeting peptide as described herein (e.g., AAV9 with a CPP 16 inserted
therein, also
referred to herein as AAV.CPP16) and encoding an immunotherapeutic to a
subject
who has been diagnosed with brain cancer.
In some embodiments, the methods also include co-administering a
chemotherapeutic agent. In some embodiments, the chemotherapeutic agent is a
toxin
or cytotoxic drug, including but not limited to temozolamide, lomustine, or a
combination thereof See, e.g., Herrlinger et al., Lancet. 2019 Feb
16;393(10172):678-688. The methods can also include administering radiation,
surgical resection, or both.
Pharmaceutical Compositions and Methods of Administration
The methods described herein include the use of pharmaceutical compositions
comprising AAVs comprising (i) the targeting peptides and (ii) sequences
encoding
an immunotherapeutic as an active ingredient.
Pharmaceutical compositions typically include a pharmaceutically acceptable
carrier. As used herein the language "pharmaceutically acceptable carrier"
includes
saline, solvents, dispersion media, coatings, antibacterial and antifungal
agents,
isotonic and absorption delaying agents, and the like, compatible with
pharmaceutical
administration.
Pharmaceutical compositions are typically formulated to be compatible with
its intended route of administration. Examples of routes of administration
include
21
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
parenteral, e.g., intravenous, intraarterial, subcutaneous, intraperitoneal
intramuscular
or injection or infusion administration. Delivery can thus be systemic or
localized.
Methods of formulating suitable pharmaceutical compositions are known in
the art, see, e.g., Remington: The Science and Practice of Pharmacy, 21st ed.,
2005;
and the books in the series Drugs and the Pharmaceutical Sciences: a Series of
Textbooks and Monographs (Dekker, NY). For example, solutions or suspensions
used for parenteral application can include the following components: a
sterile
diluent such as water for injection, saline solution, fixed oils, polyethylene
glycols,
glycerine, propylene glycol or other synthetic solvents; antibacterial agents
such as
benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or
sodium
bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers
such as
acetates, citrates or phosphates and agents for the adjustment of tonicity
such as
sodium chloride or dextrose. pH can be adjusted with acids or bases, such as
hydrochloric acid or sodium hydroxide. The parenteral preparation can be
enclosed in
ampoules, disposable syringes or multiple dose vials made of glass or plastic.
Pharmaceutical compositions suitable for injectable use can include sterile
aqueous solutions (where water soluble) or dispersions and sterile powders for
the
extemporaneous preparation of sterile injectable solutions or dispersion. For
intravenous administration, suitable carriers include physiological saline,
bacteriostatic water, Cremophor ELTM (BASF, Parsippany, NJ) or phosphate
buffered
saline (PBS). In all cases, the composition must be sterile and should be
fluid to the
extent that easy syringability exists. It should be stable under the
conditions of
manufacture and storage and must be preserved against the contaminating action
of
microorganisms such as bacteria and fungi. The carrier can be a solvent or
dispersion
medium containing, for example, water, ethanol, polyol (for example, glycerol,
propylene glycol, and liquid polyetheylene glycol, and the like), and suitable
mixtures
thereof. The proper fluidity can be maintained, for example, by the use of a
coating
such as lecithin, by the maintenance of the required particle size in the case
of
dispersion and by the use of surfactants. Prevention of the action of
microorganisms
can be achieved by various antibacterial and antifungal agents, for example,
parabens,
chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases,
it will
be preferable to include isotonic agents, for example, sugars, polyalcohols
such as
mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption
of the
22
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
injectable compositions can be brought about by including in the composition
an
agent that delays absorption, for example, aluminum monostearate and gelatin.
Sterile injectable solutions can be prepared by incorporating the active
compound in the required amount in an appropriate solvent with one or a
combination
of ingredients enumerated above, as required, followed by filtered
sterilization.
Generally, dispersions are prepared by incorporating the active compound into
a
sterile vehicle, which contains a basic dispersion medium and the required
other
ingredients from those enumerated above. In the case of sterile powders for
the
preparation of sterile injectable solutions, the preferred methods of
preparation are
vacuum drying and freeze-drying, which yield a powder of the active ingredient
plus
any additional desired ingredient from a previously sterile-filtered solution
thereof.
In one embodiment, the therapeutic compounds are prepared with carriers that
will protect the therapeutic compounds against rapid elimination from the
body, such
as a controlled release formulation, including implants and microencapsulated
delivery systems. Biodegradable, biocompatible polymers can be used, such as
ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen,
polyorthoesters,
and polylactic acid. Such formulations can be prepared using standard
techniques, or
obtained commercially, e.g., from Alza Corporation and Nova Pharmaceuticals,
Inc.
Liposomal suspensions (including liposomes targeted to selected cells with
monoclonal antibodies to cellular antigens) can also be used as
pharmaceutically
acceptable carriers. These can be prepared according to methods known to those
skilled in the art, for example, as described in U.S. Patent No. 4,522,811.
The pharmaceutical compositions can be included in a kit, container, pack, or
dispenser together with instructions for administration.
EXAMPLES
The invention is further described in the following examples, which do not
limit the scope of the invention described in the claims.
Materials and Methods
The following materials and methods were used in the Examples below.
1. Generation of capsid variants
To generate the capsid variant plasmids, DNA fragments that encode the cell-
penetrating peptides (Table 3) were synthesized (GenScript), and inserted into
the
23
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
backbone of the AAV9 Rep-cap plasmid (pRC9) between amino acid position 588
and 589 (VP1 amino acid numbering), using CloneEZ seamless cloning technology
(GenScript). CPPs BIP1(VPALR, SEQ ID NO:1) and BIP2 (VSALK, SEQ ID NO:2),
as well as their derivatives such as TVSALK (SEQ ID NO:4) in AAV.CPP.16 and
TVSALFK (SEQ ID NO:8) in AAV.CPP.21, are derived from the Ku70 proteins, of
which the sequences are provided as below:
Human Ku70 MSGWESYYKTEGDEEAEEEQEENLEASGDYKYSGRDSLIFLVDASKAMFESQSEDELTPF 60
Mouse Ku70 MSEWESYYKTEGEEEEEE--EESPDTGGEYKYSGRDSLIFLVDASRAMFESQGEDELTPF 58
Rat KU70 MSEWESYYKTEGEEEEEE--EQSPDTNGEYKYSGRDSLIFLVDASRAMFESQGEDELTPF 58
Human Ku70 DMSIQCIQSVYISKIISSDRDLLAVVFYGTEKDKNSVNFKNIYVLQELDNPGAKRILELD 120
Mouse Ku70 DMSIQCIOVYTSKIISSDRDLLAVVFYGTEKDKNSVNFKNIYVWDLDNPGAKRVLELD 118
Rat KU70 DMSIQCIQSVYTSKIISSDRDLLAVVFYGTEKDKNSVNFKSIYVLQDLDNPGAKRVLELD
118
Human Ku70 QFKGQQGQKRFQDMMGHGSDYSLSEVLWVCANLFSDVQFKMSHKRIMLFTNEDNPHGNDS 180
Mouse Ku70 QFKGQQGKKHFRDTVGHGSDYSLSEVLWVCANLFSDVQLKMSHKRIMLFTNEDDPHGRDS 118
Rat Ku70 RFKGQQGKKHFRDTIGHGSDYSLSEVLWVCANLFSDVQFKMSHKRIMLFTNEDDPHGNDS
178
Human Ku70 AKASRARTKAGDLRDTGIFLDLMHLKKPGGFDISLFYRDIISIAEDEDLRVHFEESSKLE 240
Mouse Ku70 AKASRARTKASDLRDTGIFLDLMHLKKPGGFDVSVFYRDIITTAEDEDLGVHFEESSKLE 238
Rat Ku70 AKASRARTKASDLRDTGIFLDLMHLKKRGGEDVSLFYRDIISIAEDEDLGVHFEESSKLE
238
Human Ku70 DLLRKVRAKETRKRALSRLKLKLNKDIVISVGIYNLVQKALKPPPIKLYRETNEPVKTKT 300
Mouse Ku70 DLLRKVRAKETKKRVLSRLKFKLGEDVVLMVGIYNLVQKANKPFPVRLYRETNEPVKTKT 298
Rat Ku 70 DLLRKVRAKETKKRVLSRLKFKLGKDVALMVGVYNLVQKANKPFPVRLYRETNEPVKTKT
298
Human Ku70 RTFNTSTGGLLLPSDTKRSQIYGSROILEKEETEELKRFDDPGLMLMGFKPLVLLKKHH 360
Mouse Ku70 RTFNVNTGSLLLPSDTKRSLTYGTROVLEKEETEELKRFDEPGLILMGFKPTVMLKKQH 358
Rat Ku70 RTFNVNTGSLLLPSDTKRSLTFGTRQIVLEKEETEELKRFDEPGLILMGFKPMVMLKNHH 358
Human Ku70 YLRPSLFVYPEESLVIGSSTLFSALLIKCLEKEVAALCRYTPRRNIPPYFVALVPQEEEL 420
Mouse Ku70 YLRPSLFVYPEESLVSGSSTLFSALLTKCVEKEVIAVCRYTPRKNVSPYFVALVPQEEEL 418
Rat Ku70 YLRPSLFLYPEESLVNGSSTLFSALLTKCVEKEVIAVCRYTARKNVSPYFVALVPQEEEL
418
Human Ku70 DDQKIQVTPPGFQLVFLPFADDKRKMPFTEKIMATPEQVGKMKAIVEKLRFTYRSDSFEN 480
Mouse Ku70 DDQNIQVTPGGFQLVFLPYADDKRKVPFTEKVTANQEQIDKMKAIVQKLRFTYRSDSFEN 478
Rat Ku70 DDQNIQVTPAGFQLVFLPYADDKRKVPFTEKVMANPEQIDKMKAIVQKLRFTYRSDSFEN
478
Human Ku70 PVLQQHFRNLEALALDLMEPEQAVDLTLPKVEAMNKRLGSLVDEFKELVYPPDYNPEGKV 540
Mouse Ku70 PVLQQHFRNLEALALDMMESEQVVDLTLPKVEAIKKRLGSLADEFKELVYPPGYNPEGKV 538
Rat Ku70 PVLQQHFRNLEALALDMMESEQVVDLTLPKVEAIKKRLGSLADEFKELVYPPGYNPEGKI
538
24
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
Human Ku70 TKRKHDNEGSGSKRPKVEYSEEELKTHISKGTLGKFTVPMLKEACRAYGLKSGLKKQELL 600
Mouse Ku70 AKRKQDDEGSTSKKPKVELSEEELKAHFRKGTLGKLTVPTLKDICKAHGLKSGPKKQELL 598
Rat Ku70 AKRKADNEGSASKKPKVELSEEELKDLFAKGTLGKLTVPALRDICKAYGLKSGPKKQELL
598
Human Ku70 EALTKHFQD- 609 (SEQ ID NO:86)
Mouse Ku70 DALIRHLEKN 608 (SEQ ID NO:87)
Rat Ku70 EALSRHLEKN 608 (SEQ ID NO:88)
In addition, VP1 protein sequences for AAV9, AAV.CPP.16 and
AAV.CPP.21 are provided as below:
AAV9 MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLD 60
AAV.CPP16 MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLD 60
AAV.CPP21 MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLD 60
AAV9 KGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRNVFQ
120
AAV.CPP16 KGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRNVFQ 120
AAV.CPP21 KGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFURLKEDTSFGGNLGRAVFQ 120
AAV9 AKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTE 180
AAV.CPP16 AKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTE 180
AAV.CPP21 AKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTE 180
AAV9 SVPDPQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVI
240
AAV.CPP16 SVPDPQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVI 240
AAV.CPP21 SVPDPQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVI 240
AAV9 TTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQR
300
AAV.CPP16 TTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQR 300
AAV.CPP21 TTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQR 300
AAV9 LINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAH
360
AAV.CPP16 LINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAH 360
AAV.CPP21 LINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAH 360
AAV9 EGCLPPFPADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENV
420
AAV.CPP16 EGCLPPFPADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENV 420
AAV.CPP21 EGCLPPFPADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENV 420
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
AAV9 PFHSSYARSQSLDRLMNPLIDULYYLSKTINGSGQNQQTLKFSVAGPSNMAVOGRNYIP
480
AAV.CPP16 PFHSSYARSQSLDRLMNPLIDULYYLSKTINGSGQNQQTLKFSVAGPSNMAVOGRNYIP 480
AAV.CPP21 PFHSSYARSQSLDRLMNPLIDULYYLSKTINGSGQNQQTLKFSVAGPSNMAVOGRNYIP 480
AAV9 GPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGS 540
AAVCPP16 GPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGS 540
AAV.CPP21 GPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGS 540
AAV9 LIFGKQGTGRDNVDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQ -- AQAQT 593
AAV.CPP16 LIFGKQGTGRDNVDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQTVSAL-KAQAQT 599
AAV.CPP21 LIFGKQGTGRDNVDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQTVSALFKAQAQT 600
AAV9 GWVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPETQILIKNTP
653
AAV.CPP16 GWVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTP 659
AAV.CPP21 GWVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTP 660
AAV9 VPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEF
713
AAVCPP16 VPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEF 719
AAV.CPP21 VPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEF 720
AAV9 AVNTEGVYSEPRPIGTRYLTRNL 736 (SEQ ID NO:85)
AAV.CPP16 AVNTEGVYSEPRPIGTRYLTRNL 742 (SEQ ID NO:89)
AAV.CPP21 AVNTEGVYSEPRPIGTRYLTRNL 743 (SEQ ID NO:90)
2. Recombinant AAV production
Recombinant AAVs were packaged using standard three-plasmid co-
transfection protocol (pRC plasmid, pHelper plasmid and pAAV plasmid). pRC9
(or
its variant), pHelper and pAAV carrying a transgene (e.g. nucleus-directed RFP
H2B-
mCherry driven by an ubiquitous EFla promoter) were co-transfected into HEK
293T
cells using polyethylenimine (PEI, Polysciences). rAAVs vectors were collected
from
serum-free medium 72h and 120h post transfection and from cell at 120h post
transfection. AAV particles in the medium were concentrated using a PEG-
precipitation method with 8% PEG-8000 (wt/vol). Cell pellets containing viral
particles were resuspended and lysed through sonication. Combined viral
vectors
from PEG-precipitation and cell lysates were treated with DNase and RNase at
37 C
for 30mins and then purified by iodixanol gradient (15%, 25%, 40% and 60%)
with
ultracentrifugation(VTi 50 rotor, 40,000 r.p.m, 18 C, 1h). rAAVs were then
concentrated using Millipore Amicon filter unit (UFC910008, 100K MWCO) and
26
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
formulated in Dulbecco's phosphate buffered saline (PBS) containing 0.001%
Pluronic F68 (Gibco).
3. AAV titering
Virus titer was determined by measuring DNase-resistant genome copies using
quantitative PCR. pAAV-CAG-GFP was digested with PVUII(NEB) to generate free
ends for the plasmid ITRs, and was used for generating a standard curve. Virus
samples were incubated with DNase Ito eliminate contaminating DNA, followed by
sodium hydroxide treatment to dissolve the viral capsid and to release the
viral
genome. Quantitative PCR was performed using an ITR Forward primer 5'-
GGAACCCCTAGTGATGGAGTT (SEQ ID NO:91) and an ITR Reverse primer 5'-
CGGCCTCAGTGAGCGA (SEQ ID NO:92). Vector titers were normalized to the
rAAV-2 reference standard materials (RSMs, ATCC, cat No:VR-1616, Manassas,
VA).
4. Administration of AAV in mice
For intravenous administration, AAV diluted in sterile saline (0.2 ml) was
administered through tail vein injection in adult mice (over 6 weeks of age).
Animals
then survived for three weeks before being euthanized for tissue harvesting.
For
intracerebral injection, AAV diluted in PBS (10 ul) was injected using a
Hamilton
syringe with coordinates from bregma: 1.0 mm right, 0.3 backward, 2.6 mm deep.
All
animal studies were performed in an AAALAC-accredited facility with IACUC
approval.
5. Mouse tissue processing
Anesthetized animals were transcardially perfused with cold phosphate
buffered saline (PBS) followed by 4% paraformaldehyde (PFA). Tissues were post-
fixed in 4% PFA overnight, and then immersed in 30% sucrose solutions for two
days
prior to embedding and snap-freezing in OCT. Typically, 80 um thick brain
sections
were cut for imaging of native fluorescence, 40um thick brain sections for
IHC.
6. In vitro human BBB spheroid model
Hot 1% agarose (w/v, 50 ul) was added in a 96-well plate to cool/solidify.
Primary human astrocytes (Lonza Bioscience), human brain microvascular
pericytes
(HBVP, ScienCell Research Laboratories) and human cerebral microvascular
27
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
endothelial cells (hCMEC/D3; Cedarlane) were then seeded onto the agarose gel
in a
1:1:1 ratio (1500 cells of each type). Cells were cultured at 37 C in a 5% CO2
incubator for 48-72 hours to allow for spontaneous assembly of multicellular
BBB
spheroids. A multicellular barrier was reported to form at the periphery of
the
spheroid, mimicking the BBB. AAVs-H2B-mCherry were added to the culture
medium, and 4 days later all spheroids were fixed using 4% PFA, transferred
into a
Nunc Lab-Tek II thin-glass 8-well chambered coverglass (Thermo Scientific),
and
imaged using a Zeiss LSM710 confocal microscope. The intensity of RFP signal
inside the spheroids was examined and used as a "read-out".
7. AAV administration in non-human primate (NHP)
All NHP studies were performed by a CRO in an AAALAC-accredited facility
with IACUC approval. Cynomolgus monkeys were pre-screened for little or no pre-
existing neutralizing antibody against AAV9 (titer of <1:5). AAV diluted in
PBS/0.001%F68 was injected intravenously (via cephalic vein or femoral vein)
using
a peristaltic pump. 3 weeks later, animals were subject to transcardial
perfusion with
PBS, followed by 4% PFA. Tissues were then collected and processed for
paraffin
embedding and sectioning.
8. Immunohistochemistry
Floating staining was performed for mouse tissue sections with primary
antibodies diluted in PBS containing 10% donkey serum and 2% Triton X-100.
Primary antibodies used include: chicken anti-GFP (1:1000); rabbit anti-RFP
(1:1000); mouse anti-NeuN (1:500); rat anti-GFAP(1:500); Goat anti-
GFAP(1:500);
mouse anti-CD31(1:500). Secondary antibodies conjugated to fluorophores of
Alexa
Fluor 488, Alexa Fluor 555 or Alexa Fluor 647 were applied against the primary
antibody's host species at a dilution of 1:200.
For paraffin sections of NHP tissue, DAB staining was performed to visualize
cells transduced by AAV-AADC. Rabbit anti-AADC antibody (1:500, Millipore) was
used as primary antibody.
9. AAV binding assay
HEK293T cells were cultured at 37 C in a 5% CO2 incubator. One day after
seeding of HEK293T cells in a 24-well plate at a density of 250,000 cells per
well, a
28
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
cDNA plasmid of LY6A was transiently transfected into the cells using a
transfection
mixture of 200u1DMEM (31053028; Gibco), 1 ug DNA plasmid and 3ug of PEI. 48
hours post transfection, cells were placed on ice to chill down for 10 mins.
The
medium was then changed with 500u1 ice-cold serum-free DMEM medium containing
rAAVs-mCherry at MOT of 10000. After incubating on ice for one hour, cells
with
presumably AAVs bound to their surface were washed with cold PBS for three
times
and were then subject to genomic DNA isolation. Cell-binding viral particles
were
quantified by using qPCR with primers specific to mCherry and normalized to
HEK293T genomes using human GCG as reference.
10. Mouse model of glioblastoma
All experiments were performed in compliance with protocols approved by the
Animal Care and Use Committees (IACUC) at the Brigham and Women's Hospital
and Harvard Medical School. Syngeneic immuno-competent C57BL/6 female mice
weighing 20 +/- 1 g (Envigo) were used. GL261-Luc (100,000 mouse glioblastoma
cells) resuspended in 2[iL phosphate buffered saline (PBS) was injected
intracranially
using 10111 syringe with a 26-gauge needle (80075; Hamilton). A stereotactic
frame
was used to locate the implantation site (coordinates from bregma in mm: 2
right, 0.5
forward, at a depth of 3.5 into cortex). 7 days later, 200 ul AAV-HSV-TK1
(1E+12
viral genomes, IV) was administered once and ganciclovir (50 mg/kg) was
administered daily for 10 days.
Example 1. Modification of AAV9 capsid
To identify peptide sequences that would enhance permeation of a
biomolecule or virus across the blood brain barrier an AAV peptide display
technique
was used, individual cell-penetrating peptides, as listed in Table 3, were
inserted into
.. the AAV9 capsid between amino acids 588 and 589 (VP1 numbering) as
illustrated in
FIG. 1A. The insertion was carried out by modifying the RC plasmid, one of the
three
plasmids co-transfected for AAV packaging; FIG. 1B shows an exemplary
schematic
of the experiments. Individual AAV variants were produced and screened
separately.
See Materials and Methods #1-3 for more details.
29
CA 03167290 2022-07-08
WO 2021/142300 PCT/US2021/012746
TABLE 3
No. of
Name of CPP Viral
AAV Amino acid sequence
of CPP #
CPP insert residue titer
s
AAV9 N/A N/A N/A
Normal
AAV.CPP .1 SynB1
RGGRLSYSRRRFSTSTGR 93 18 Low
AAV.CPP .2 L-2 HARIKPTFRRLKWKY 94 20 Low
KGKFW
AAV.CPP .3 Pre S2-TLM PLSSIFSRIGDP 95 12 Low
AAV.CPP .4 Transportan AGYLLGKINLKALAA 96 21 Low
a 10 LAKKIL
=
*E AAV.CPP .5 SAP VRLPPPVRLPPPVRLPPP 97 18
Normal
<1.)
LI! AAV.CPP .6 SAP(E) VELPPPVELPPPVELPPP
98 18 Normal
c.4
AAV.CPP .7 SVM3 KGTYKKKLMRIPLKGT 99 16 Low
:A.! AAV.CPP .8 (PPR)3 PPRPPRPPR 100 9
Normal
=
1-1 AAV.CPP .9 (PPR)5 PPRPPRPPRPPRPPR 101 15 Low
AAV. CPP. 10 Polyarginin RRRRRRRR 102 8 Low
e
AAV.CPP.11 Bipl VPALR 1 5
Normal
AAV.CPP.12 Bip2 VSALK 2 5
Normal
AAV.CPP.13 DPV15 LRRERQ SRLRRERQ SR 103 16 NA
AAV. CPP. 14 HIV-1 Tat RKKRRQRRR 104 9 NA
AAV.CPP.15 Bip1.1 TVPALR (Rat) 3 6
Normal
a
=E, AAV.CPP.16 Bip2.1 TVSALK (Syn)
4 6 Normal
=
t AAV.CPP.17 Bip2.2 FTVSALK (Syn) 5 7
Normal
µ.
5)' AAV.CPP.18 Bip2.3 LTVSALK (Syn) 6 7
Normal
sm.
AAV.CPP.19 Bip2.4 KFTVSALK (Syn) 72 8
Normal
g AAV.CPP.20 Bip2.5 TFVSALK (Syn) 7 7
Normal
-5 AAV.CPP.21 Bip2.6 TVSALFK (Syn) 8 7
Normal
AAV.CPP.22 Bip2.6Rat TVPALFR (Rat) 9 7
Normal
#, SEQ ID NO:
Syn, synthetic
Example 2. First Round of in vivo screening
5 AAVs expressing nuclear RFP (H2B-RFP) were injected intravenously in
adult mice with mixed C57BL/6 and BALB/c genetic background. 3 weeks later,
brain tissues were harvested and sectioned to reveal RFP-labelled cells (white
dots in
FIGs. 2A and 2C, quantified in FIGs. 2B and 2D, respectively). CPPs BIP1 and
BIP2
were inserted into the capsids of AAV.CPP.11 and AAV.CPP.12, respectively. See
10 Materials and Methods #4-5 for more details.
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
Example 3. Optimization of modified AAV9 capsids
AAV.CPP.11 and AAV.CPP.12 were further engineered by optimizing the
BIP targeting sequences. BIP inserts were derived from the protein Ku70 (See
FIG.
3A and Material/Methods #1 for full sequence). The BIP sequence VSALK, which
is
of "synthetic" origin, was chosen as a study focus to minimize potential
species
specificity of engineered AAV vectors. AAVs were produced and tested
separately
for brain transduction efficiency as compared with AAV9 (see FIGs. 3B-C).
Percentages of cell transduction in the mouse liver 3 weeks after IV injection
of some
AAV variants delivering the reporter gene RFP are shown in FIG. 3D. See
Materials
and Methods #1-5 for more details.
Example 4. In vitro model - BBB permeation screening
Some of the AAV variants were screened for the ability to cross the human
BBB using an in vitro spheroid BBB model. The spheroid contains human
microvascular endothelial cells, which form a barrier at the surface, and
human
pericytes and astrocytes. AAVs carrying nuclear RFP as reporter were assessed
for
their ability to penetrate from the surrounding medium into the inside of the
spheroid
and to transduce the cells inside. FIG. 4A shows an experimental schematic.
FIGs.
4B-D show results for wt AAV9, AAV.CPP.16, and AAV.CPP.21, respectively, those
and other peptides are quantified in FIG. 4E. In this model, peptides 11, 15,
16, and
21 produced the greatest permeation into the spheroids. See Materials and
Methods #6
for more details.
Example 5. In vivo BBB permeation screening
AAV.CPP.16 and AAV.CPP.21 were selected for further evaluation in an in
vivo model, in experiments performed as described above for Example 2. All
AAVs
carried nuclear RFP as reporter. Both showed enhanced ability vs. AAV9 to
transduce brain cells after intravenous administration in C57BL/6J adult mice
(white
dots in brain sections in FIG. 5A, quantified in FIG. 5B) and in BALB/c adult
mice
(white dots in brain sections in FIG. 6A, quantified in FIG. 6B).
High doses of AAV.CPP.16 and AAV.CPP.21 (4 x 1012 vg per mouse,
administered IV) resulted in widespread brain transduction in mice. Both AAVs
carried nuclear RFP as reporter (white dots in brain sections in FIG. 7A,
quantified in
FIG. 7B).
31
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
Example 6. In vivo distribution of modified AAVs
As shown in FIG. 8A, AAV.CPP.16 and AAV.CPP.21 preferentially targeted
neurons (labeled by a NeuN antibody) across multiple brain regions in mice
including
the cortex, midbrain and hippocampus. Both AAVs carried nuclear RFP as a
reporter.
AAV.CPP.16 and AAV.CPP.21 also showed enhanced ability vs. AAV9 in
targeting the spinal cord and motor neurons in mice. All AAVs carry nuclear
RFP as
reporter and were administered intravenously into neonate mice (4 x 1010 vg).
Motor
neurons were visualized using CHAT antibody staining. Co-localization of RFP
and
CHAT signals in FIG. 8B suggested specific transduction of the motor neurons.
The relative abilities of AAV-CAG-H2B-RFP and AAV.CPP.16-CAG-H2B-
RFP to transduce various tissues in mice was also evaluated. 1 x 1011 vg was
injected
intravenously. The number of cells transduced was normalized to the number of
total
cells labeled by DAPI nuclear staining. The results showed that AAV.CPP.16 was
more efficient than AAV9 in targeting heart (FIG. 9A); skeletal muscle (FIG.
9B),
and dorsal root ganglion (FIG. 9C) tissue in mice.
Example 7. BBB permeation in a non-human primate model
2 x 1013 vg/kg AAVs-CAG-AADC (as reporter gene) were injected
intravenously into 3-month-old cynomolgus monkeys. AAV-transduced cells (shown
in black) were visualized using antibody staining against AADC. As shown in
FIGs.
10A-D, AAV.CPP.16 and AAV.CPP.21 showed enhanced ability vs. AAV9 to
transduce brain cells after intravenous administration in non-human primates.
AAV.CPP.16 transduced significantly more cells then wt AAV9 in the primary
visual
cortex (FIG. 10A), parietal cortex (FIG. 10B), thalamus (FIG. 10C), and
cerebellum
(FIG. 10D). See Materials and Methods #7-8 for more details.
Example 8. AAV.CPP.16 and AAV.CPP.21 do not bind to LY6A
LY6A serves as a receptor for AAV.PHP.eB and mediates AAV.PHP.eB's
robust effect in crossing the BBB in certain mouse strains. Over-expressing
mouse
LY6A in cultured 293 cells significantly increased binding of AAV.PHP.eB to
the
cell surface (see FIG. 11A). On the contrary, over-expressing LY6A does not
increase
viral binding for AAV9, AAV.CPP.16 or AAV.CPP.21 (see FIG. 11B). This suggests
AAV.CPP.16 or AAV.CPP.21 does not share LY6A with AAV.PHP.eB as a receptor.
See Materials and Methods #9 for more details.
32
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
Example 9. Delivering therapeutic proteins to the brain using
AAV.CPP.21
AAV.CPP.21 was used to systemically deliver the "suicide gene" HSV.TK1 in
a mouse model of brain tumor (Materials and Methods #10). HSV.TK1 turns the
otherwise "dormant" ganciclovir into a tumor-killing drug. Intravenously
administered AAV.CPP.21-H2BmCherry (FIG. 12A, bottom left and middle right
panel) was shown to target tumor mass, especially the tumor expanding
frontier. As
shown in FIGs. 12B-C, using AAV.CPP.21 to systemically deliver the "suicide
gene"
HSV.TK1 resulted in shrinkage of brain tumor mass, when combined with the pro-
drug ganciclovir. These results show that AAV.CPP.21 can be used to
systemically
deliver a therapeutic gene into brain tumor. See Materials and Methods #10 for
more
details.
Example 10. Intracerebral administration of AAV.CPP.21
In addition to systemic administration (such as in Example 2), an AAV as
described herein was administered locally into the mouse brain. Intracerebral
injection
of AAV9-H2B-RFP and AAV.CPP.21-H2B-RFP (FIG. 13) resulted in more
widespread and higher-intensity RFP signal in AAV.CPP.21-treated brain
sections vs.
AAV9-treated ones. See Materials and Methods #4 for more details.
Example 11. Systemic Delivery of AAV.CPP.16 to the Glioblastoma
Tumor Microenvironment
Using systemic administration (such as in Example 2), delivery of an AAV as
described herein into the brains of an orthotopic, immunocompetent mouse
glioblastoma model (GL261 model). (as described in Materials and Methods #10).
As
shown in FIG. 14, AAV.CPP16 far outperformed AAV9, with significant delivery
both to tumors and to the surrounding microenvironment.
To determine whether this increased efficiency of delivery would translate to
improved therapeutic efficacy, various treatments were administered to the
mouse
GBM model; FIG. 15A provides a schematic of the experimental protocol. The
results, shown in FIGs. 15B-C, demonstrated that AAV.CPP.16-antiPD-L1 mediated
immunotherapy significantly prolonged survival in the murine GBM model. As
shown in FIG. 15B, 1 of 8 mice treated with AAV9-antiPD-L1 survived long term,
while 6/8 mice treated with the AAV.CPP.16-antiPD-L1 survived long term
(longer
33
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
than 100 days). FIG. 15C shows that all 6 of the long-term survivors (five
treated
with AAV.CPP.16-antiPD-L1 plus one treated with AAV9-antiPD-L1; one of the
long-term survivors treated with AAV.CPP.16-antiPD-L1 died during re-
challenging
surgery due to technical reasons) were still alive 200 days after tumor
implantation.
Thus, intravenous injection of AAV.CPP.16 expressing an antibody targeting the
mouse PD-Li eradicated GBM tumors in 75% of the mice, whereas untreated mice
died within a month of tumor implantation.
The long-term surviving mice were sacrificed at 200 days, and their brains
examined. As shown in FIG. 16A, no evidence of tumors remained. FIG. 16B shows
a bioluminescent image taken of one of the mice that had extended survival,
showing
that at 7 days post implant the tumor cells were present. FIG. 16C shows that
the
initial tumor implantation is devoid of residual tumor and only gliotic scar
tissue
remains, indicating complete tumor eradication.
Furthermore, immunohistochemistry showed that CB8+ cytotoxic T cells were
also present in the GBM tumor site, further evidence for an immune reaction.
Example 12. Expression of HA-tagged antiPD-L1 antibody in GBM
tumor
Expression of HA-tagged antiPD-L1 antibody in GBM tumor as measured by
Western blotting is shown in FIGS. 17A-17B. AAVs of 1e12 vg or PBS were
injected
intravenously 5 days after tumor implantation in mice. Tumor tissues were
harvested
14 days after IV injection. The intensities of HA tag staining (FIG. 17A) were
quantified as measurement of antiPD-L1 antibody expression (FIG. 17B).
References
1. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant
temozolomide for glioblastoma. The New England journal of medicine 352, 987-
996
(2005).
2 Ostrom, Q. T. et al. CBTRUS Statistical Report: Primary
brain and
other central nervous system tumors diagnosed in the United States in 2010-
2014.
Neuro-oncology 19, vi-v88 (2017).
3 Brennan, C. W. et al. The somatic genomic landscape of glioblastoma.
Cell 155, 462-477 (2013).
34
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
4 Lim, M., Xia, Y., Bettegowda, C. & Weller, M. Current state
of
immunotherapy for glioblastoma. Nature reviews. Clinical oncology 15, 422-442
(2018).
Perry, A. & Wesseling, P. Histologic classification of gliomas.
5 Handbook of clinical neurology 134, 71-95 (2016).
6 Wen, P. Y. & Kesari, S. Malignant gliomas in adults. The New
England journal of medicine 359, 492-507 (2008).
7 Jain, R. K. et al. Angiogenesis in brain tumours. Nature
reviews.
Neuroscience 8, 610-622 (2007).
8 Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M. & Sah,
D. W. Y. Gene therapy for neurological disorders: progress and prospects.
Nature
reviews. Drug discovery (2018).
9 Hudry, E. & Vandenberghe, L. H. Therapeutic AAV Gene
Transfer to
the Nervous System: A Clinical Reality. Neuron 101, 839-862 (2019).
10 Batista, A. R. et al. Ly6a differential expression in BBB is responsible
for strain specific CNS transduction profile of AAV-PHP.B. Human gene therapy
(2019).
11 Hordeaux, J. et al. The GPI-Linked Protein LY6A Drives AAV-
PHP.B
Transport across the Blood-Brain Barrier. Molecular therapy : the journal of
the
American Society of Gene Therapy 27, 912-921 (2019).
12 Huang, Q. et al. Delivering genes across the blood-brain
barrier:
LY6A, a novel cellular receptor for AAV-PHP.B capsids. PloS one 14, e0225206
(2019).
13 Hordeaux, J. et al. The Neurotropic Properties of AAV-PHP.B
Are
.. Limited to C57BL/6J Mice. Molecular therapy : the journal of the American
Society
of Gene Therapy 26, 664-668 (2018).
14 Matsuzaki, Y. et al. Intravenous administration of the adeno-
associated
virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset
brain.
Neuroscience letters 665, 182-188 (2018).
15 Nakashima, H. et al. Modeling tumor immunity of mouse glioblastoma
by exhausted CD8(+) T cells. Scientific reports 8, 208 (2018).
16 Reul et al., Tumor-Specific Delivery of Immune Checkpoint
Inhibitors
by Engineered AAV Vectors. Front Oncol. 2019 Feb 14;9:52.
CA 03167290 2022-07-08
WO 2021/142300
PCT/US2021/012746
17 Engeland et al., CTLA-4 and PD-Li Checkpoint Blockade Enhances
Oncolytic Measles Virus Therapy. Molecular Therapy 22(11):1949-1959 Nov. 2014.
OTHER EMBODIMENTS
It is to be understood that while the invention has been described in
conjunction with the detailed description thereof, the foregoing description
is intended
to illustrate and not limit the scope of the invention, which is defined by
the scope of
the appended claims. Other aspects, advantages, and modifications are within
the
scope of the following claims.
36
